Increased risk of Parkinson's disease in individuals hospitalized with conditions related to the use of methamphetamine or other amphetamine-type drugs

Drug and Alcohol Dependence

Volumn 120, Issue 1-3, 2012, Pages 35-40

  Callaghan, Russell C ^a,b   Cunningham, James K ^c   Sykes, Jenna ^a   Kish, Stephen J ^a,b  

^a CENTRE FOR ADDICTION AND MENTAL HEALTH   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c UNIVERSITY OF ARIZONA COLLEGE OF MEDICINE   (United States)

Author keywords

Amphetamine; Cocaine; Cohort studies; Dopamine; Incidence; Methamphetamine; Movement disorders; Parkinson's disease

Indexed keywords

AMPHETAMINE; METHAMPHETAMINE;

ADULT; APPENDICITIS; ARTICLE; COCAINE DEPENDENCE; COHORT ANALYSIS; CONTROLLED STUDY; DRUG DEPENDENCE; FEMALE; HOSPITAL PATIENT; HUMAN; MAJOR CLINICAL STUDY; MALE; PARKINSON DISEASE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RISK ASSESSMENT; RISK FACTOR;

ADULT; AMPHETAMINE-RELATED DISORDERS; AMPHETAMINES; APPENDICITIS; CASE-CONTROL STUDIES; COCAINE-RELATED DISORDERS; FEMALE; HOSPITALIZATION; HUMANS; MALE; METHAMPHETAMINE; MIDDLE AGED; PARKINSON DISEASE, SECONDARY; PROPENSITY SCORE; RETROSPECTIVE STUDIES; RISK FACTORS;

EID: 84155165436     PISSN: 03768716     EISSN: 18790046     Source Type: Journal    
DOI: 10.1016/j.drugalcdep.2011.06.013     Document Type: Article

References (47)

1. Allam M.F., Campbell M.J., Hofman A., Del Castillo A.S., Navajas R.F.C. Smoking and Parkinson's disease: systematic review of prospective studies. Mov. Disord. 2004, 19:614-621.
2. Austin P.C. A critical appraisal of propensity-score matching in the medical literature between 1996 and 2003. Stat. Med. 2008, 27:2037-2049.
3. Austin P.C. Some methods of propensity-score matching had superior performance to others: results of an empirical investigation and Monte Carlo simulations. Biom. J. 2009, 51:171-184.
4. Austin P.C., Mamdani M.M. A comparison of propensity score methods: a case-study estimating the effectiveness of post-AMI statin use. Stat. Med. 2006, 25:2084-2106.
5. Boileau I., Rusjan P., Houle S. Increased vesicular monoamine transporter binding during early abstinence in human methamphetamine users: is VMAT2 a stable dopamine neuron biomarker?. J. Neurosci. 2008, 28:9850-9856.
6. Caligiuri M.P., Buitenhuys C. Do preclinical findings of methamphetamine-induced motor abnormalities translate to an observable clinical phenotype?. Neuropsychopharmacology 2005, 30:2125-2134.
7. Callaghan R.C., Cunningham J.K., Sajeev G., Kish S.J. Incidence of Parkinson's disease among hospital patients with methamphetamine-use disorders. Mov. Disord. 2010, 25:2333-2339.
8. Callaghan R.C., Khizar A. The incidence of cardiovascular morbidity among patients with bipolar disorder: a population-based longitudinal study in Ontario, Canada. J. Affect. Disord. 2010, 122:118-123.
9. Card T.R., Solaymani-Dodaran M., Hubbard R., Logan R.F., West J. Is an internal comparison better than using national data when estimating mortality in longitudinal studies?. J. Epidemiol. Community Health 2006, 60:819-821.
10. Cunningham J.K., Liu L.M. Impacts of federal ephedrine and pseudoephedrine regulations on methamphetamine-related hospital admissions. Addiction 2003, 98:1229-1237.
11. Degenhardt L., Singleton J., Calabria B., McLaren J., Kerr T., Mehta S., Kirk G., Hall W.D. Mortality among cocaine users: a systematic review of cohort studies. Drug Alcohol Depend. 2011, 113:88-95.
12. Fibiger H.C., McGeer E.G. Effect of acute and chronic methamphetamine treatment on tyrosine hydroxylase activity in brain and adrenal medulla. Eur. J. Pharmacol. 1971, 16:176-180.
13. Guilarte T.R. Is methamphetamine abuse a risk factor in parkinsonism?. Neurotoxicology 2001, 22:725-731.
14. Guttman M., Slaughter P.M., Theriault M.E., DeDoer D.P., Naylor C.D. Burden of parkinsonism: a population-based study. Mov. Disord. 2003, 18:313-319.
15. Kalman D., Morissette S.B., George T.P. Co-morbidity of smoking in patients with psychiatric and substance use disorders. Am. J. Addict. 2005, 14:106-123.
16. Kish S.J. Pharmacologic mechanisms of crystal meth. CMAJ 2008, 178:1679-1682.
17. Lin H.C., Tsai S.Y., Lee H.C. No higher risk of myocardial infarction among bipolar patients in a 6-year follow-up of acute mood episodes. Psychosom. Med. 2008, 70:73-76.
18. Lin H.C., Hsiao F.H., Pfeiffer S., Hwang Y.T., Lee H.C. An increased risk of stroke among young schizophrenia patients. Schizophr. Res. 2008, 101:234-241.
19. Little K.Y., Ramssen E., Welchko R., Volberg V., Roland C.J., Cassin B. Decreased brain dopamine cell numbers in human cocaine users. Psychiatry Res. 2009, 168:173-180.
20. 11C]WIN-35,428. J. Neurosci. 1998, 18:8417-8422.
21. Mueller B.A., Rivara F.P., Lii S.M., Weiss N.S. Environmental factors and the risk for childhood pedestrian-motor vehicle collision occurrence. Am. J. Epidemiol. 1990, 132:550-560.
22. Noyes K., Liu H., Holloway R., Dick A.W. Accuracy of Medicare claims data in identifying Parkinsonism cases: comparison with the Medicare current beneficiary survey. Mov. Disord. 2007, 22:509-514.
23. Pintilie M. Competing Risks: A Practical Perspective 2006, John Wiley and Sons, Hoboken, NJ.
24. Poikolainen K., Saarinen M., Eskola J. Acute appendicitis not associated with social class among children. Int. J. Epidemiol. 1985, 14:333-334.
25. Ricaurte G.A., Seiden L.S., Schuster C.R. Further evidence that amphetamines produce long-lasting dopamine neurochemical deficits by destroying dopamine nerve fibers. Brain Res. 1984, 303:359-364.
26. Ritz B. Pooled analysis of tobacco use and risk of Parkinson's disease. Arch. Neurol. 2007, 64:990-997.
27. Ross S.B., Kelder D. Inhibition of 3H-dopamine accumulation in reserpinized and normal rat striatum. Acta Pharmacol. Toxicol. 1979, 44:329-335.
28. Ryan L.J., Linder J.C., Martone M.E., Groves P.M. Histological and ultrastructural evidence that d-amphetamine causes degeneration in neostriatum and frontal cortex of rats. Brain Res. 1990, 518:67-77.
29. Ryan L.J., Martone M.E., Linder J.C., Groves P.M. Cocaine, in contrast to d-amphetamine, does not cause axonal terminal degeneration in neostriatum and agranular frontal cortex of Long-Evans rats. Life Sci. 1988, 43:1403-1409.
30. Sauerland S., Lefering R., Neugebauer E.A. Laparoscopic versus open surgery for suspected appendicitis. Cochrane Database Syst. Rev. 2004, 4:CD001546.
31. Seiden L.S., Fischman M.W., Schuster C.R. Long-term methamphetamine induced changes in brain catecholamines in tolerant rhesus monkeys. Drug Alcohol Depend. 1976, 1:215-219.
32. Singleton J., Degenhardt L., Hall W., Zabransky T. Mortality among amphetamine users: a systematic review of cohort studies. Drug Alcohol Depend. 2009, 105:1-8.
33. Staley J.K., Talbot J.Z., Ciliax B.J., Miller G.W., Levey A.I., Kung M., Kung H.F., Mash D.C. Radioligand binding and immunoautoradiographic evidence for a lack of toxicity to dopaminergic nerve terminals in human cocaine overdose victims. Brain Res. 1997, 747:219-229.
34. Substance Abuse and Mental Health Services Administration, 2010a. Office of Applied Studies. Drug Abuse Warning Network, 2007. National Estimates of Drug-Related Emergency Department Visits, Rockville, MD.
35. Substance Abuse and Mental Health Services Administration, 2010b. Office of Applied Studies. Treatment Episode Data Set (TEDS) 1998-2008. National Admissions to Substance Abuse Treatment Services. DASIS Series: S-50, HHS Publication No. (SMA) 09-4471.
36. Sununu, S.J., December 15, 2005. S. 2118-109th Congress: Combat Methamphetamine Epidemic Act of 2005. (accessed on May 12, 2011). http://www.govtrack.us/congress/billtext.xpd%3Fbill=s109-2118.
37. Szumski N.R., Cheng E.M. Optimizing algorithms to identify Parkinson's disease cases within an administrative database. Mov. Disord. 2009, 24:51-56.
38. Thrash B., Thiruchelvan K., Ahuja M., Suppiramaniam V., Dhanasekaran M. Methamphetamine-induced neurotoxicity: the road to Parkinson's disease. Pharmacol. Rep. 2009, 61:966-977.
39. Tse W., Cersosimo M.G., Gracies J.M., Morgello S., Olanow C.W., Koller W. Movement disorders and AIDS: a review. Parkinsonism Relat. Disord. 2004, 10:323-334.
40. Twelves D., Perkins K.S.M., Counsell C. Systematic review of incidence studies of Parkinson's disease. Mov. Disord. 2003, 18:19-31.
41. United Nations Office on Drugs and Crime, 2008. 2008 World Drug Report. United Nations Publication, Vienna, Austria.
42. Weinberger A.H., Sofuoglu M. The impact of cigarette smoking on stimulant addiction. Am. J. Drug Alcohol Abuse 2009, 35:12-17.
43. Wilson J.M., Kalasinsky K.S., Levey A.I., Bergeron C., Reiber G., Anthony R.M., Schmunk G.A., Shannak K., Haycock J.W., Kish S.J. Striatal dopamine nerve terminal markers in human, chronic methamphetamine users. Nat. Med. 1996, 2:699-703.
44. Wilson J.M., Kish S.J. The vesicular monoamine transporter, in contrast to the dopamine transporter, is not altered by chronic cocaine self-administration in the rat. J. Neurosci. 1996, 16:3507-3510.
45. Wilson J.M., Shannak K., Kish S.J., Levey A.I., Bergeron C., Deck J., Kalasinsky K., Ang L., Peretti F., Adams V.I., Smialek J., Anderson W.R., Niznik H.B. Striatal dopamine, dopamine transporter, and vesicular monoamine transporter in chronic cocaine users. Ann. Neurol. 1996, 40:428-439.
46. Zhou B., Latouche A. Competing Risks Regression for Stratified and Clustered Data. R Package Version 1.0 2011.
47. Zingmond D.S., Ye Z., Ettner S.L., Liu H. Linking hospital discharge and death records-accuracy and sources of bias. J. Clin. Epidemiol. 2004, 57:21-29.